Dr. Wang is responsible for HUYABIO’s corporate development in China. With over 25 years industry experience in global pharmaceutical research and development, alliances establishment, and business development, she leverages her experience to optimize business strategy, increase operational efficiency, and enhance cross-border cooperation. Before joining HUYABIO, Yung-Chih led projects at Ferring Pharmaceuticals in drug target identification-validation, drug screening, key collaborations of discovery programs, and strategic plan implementation.
Governance
HUYABIO is an emerging biopharmaceutical company focused on helping to solve unmet medical needs. As the pioneer in enabling and accelerating global development and commercialization of novel biopharmaceuticals from China, we take pride in the positive difference that our work makes to the lives of people around the world. Our success is grounded in our commitment to integrity, and the highest standards of quality, compliance, and safety.
San Diego, CA, USA – June 14, 2022 – HUYABIO International today announced that the first three patients had been dosed in an ongoing Phase 2 study of HUYABIO’s novel drug for pharmacological cardioversion of atrial fibrillation (AF).
Dr. Mireille Gillings, President, CEO & Executive Chair, said, “We are excited to proceed with dosing AF patients in our Phase 2 trial of HBI-3000.
Phase 1 trial evaluated the pharmacokinetics and safety of HBI-3000 when dosed with the strong CYP2D6 inhibitor, paroxetine
San Diego, CA, USA – May 17, 2022 – HUYABIO International, the leader in accelerating global development of China’s pharmaceutical innovations, today announced the successful completion of a Phase 1 drug-drug interaction clinical trial of HBI-3000, a novel drug for cardioversion of atrial fibrillation (AF).
Clinical stage drug is the fifth asset in the growing pipeline of HUYABIO’s oncology products
San Diego, CA, USA – December 2, 2021 – HUYABIO International, the leader in accelerating global development of China’s pharmaceutical innovations, announced today it had licensed exclusive worldwide ex-China rights to the KRAS inhibitor, JMKX1899, from Shanghai Jemincare Pharmaceutical Co.,
This is the second indication for Hiyasta® in Japan following adult T-cell leukemia/lymphoma (ATLL)
SAN DIEGO, November 30, 2021 /PRNewswire/ — HUYABIO International, the leader in accelerating global development of China’s pharmaceutical innovations, today announced the regulatory approval of HBI-8000, brand name Hiyasta®, monotherapy for the treatment of relapsed or refractory (R/R) PTCL by the Ministry of Health, Labour and Welfare in Japan.
Ex-China rights to the novel drug expands HUYABIO’s growing oncology pipeline
San Diego, CA, USA – November 9, 2021 – HUYABIO International, the leader in accelerating global development of China’s pharmaceutical innovations, announced today it had licensed exclusive worldwide ex-China rights to the Wee1 inhibitor from Shanghai Pharma, the second largest pharma group in China with annual sales of over $30 billion.
First patient dosed in trial investigating cardioversion of recent-onset atrial fibrillation
San Diego, CA, USA – November 2, 2021 – HUYABIO International (HUYABIO), the leader in accelerating global development of China’s pharmaceutical innovations, today announced that the first patient has been dosed in a Phase 2 study of HUYABIO’s novel drug for cardioversion of atrial fibrillation (AF) at Wellington Regional Hospital in Wellington, New Zealand.
San Diego, CA, USA – October 28, 2021 – HUYABIO International (HUYABIO™), the leader in accelerating global development of China’s pharmaceutical innovations, announced today the FDA clearance of HBI-2376 as an Investigational New Drug, or IND, for a Phase 1 study. The authorization to proceed enables the first testing in patients for whom this novel SHP2 inhibitor might show clinical benefit.
